LIXT

$3.01

Pre-MarketAs of Mar 17, 8:00 PM UTC

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Recent News

Simply Wall St.
Nov 19, 2025

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.